Fundraising Fox
Embryoxite
Techstars '25Florida, US · Founded 2020 · 11 employees on LinkedIn · 2 known investors
Find your way into Embryoxite
Sign up to see every warm intro you have to Embryoxite
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Embryoxite team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Embryoxite develops AI-powered, non-invasive embryo analysis that predicts IVF implantation success by analyzing embryo culture medium, alongside an IVF electronic medical record and clinic management platform. It serves fertility clinics and reproductive medicine specialists, offering predictive analytics for embryo selection and ovarian reserve assessment.
Also known as Embryoxite (Techstars '25)
Founders & leadership
Embryoxite was founded in 2020 by Delfina Vilieri.
Investors · 2
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Embryoxite is a biotechnology company that develops non-invasive diagnostic services for preimplantation embryos in human assisted reproduction. Its technology analyzes molecular signals in the culture medium in which an embryo develops, combining metabolomics data with time-lapse embryo images, genetics, patient clinical data and artificial intelligence to estimate the probability that a given embryo will lead to a successful pregnancy. Because the analysis is performed on the spent culture medium, it does not require embryo biopsy and is designed to fit into existing laboratory workflows without changes to clinical procedures.
The company's stated current priority is clinical validation, carried out with fertility centers in multiple regions to generate real-world evidence, alongside expansion of its technology platform to integrate clinical, imaging and molecular information into a broader model of embryo development. It was founded in 2020 and describes itself as building a global dataset from the clinics it works with.
Founding story
Delfina Vilieri, an industrial engineer and full-stack developer, spent roughly seven years in large corporations including Volkswagen, where she observed tension between women's professional growth and motherhood, then moved into entrepreneurship and built a consultancy helping startups optimize operations and scale. She applied to the accelerator Grid Exponential, where she met the scientific co-founders with whom she founded Embryoxite, combining her engineering, process and business background with their scientific expertise.
Business model
Embryoxite supplies a diagnostic/analytical service to fertility clinics and reproductive centers, which send samples of embryo culture medium and associated clinical and imaging data for AI-based analysis supporting embryo selection. Commercial relationships are established through agreements with reproductive centers.
Traction
The company reports seven signed commercial agreements and work with ten reproductive centers, analysis of 23,000 embryos and testing of more than 650 culture-medium samples, and a machine-learning model predicting clinical pregnancy at 72% accuracy. It states an aim to improve embryo selection by 75% for IVF treatment. Company listings report 11-20 employees.
Latest developments
As of 2025 the company reported that it was focused on clinical validation with fertility clinics across regions, expanding its technology platform, closing a funding round and building strategic partnerships. Founder and CEO Delfina Vilieri participated in Techstars and was profiled for work in women's health innovation.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Embryoxite positions itself in the assisted reproduction diagnostics segment as a non-invasive alternative to biopsy-based embryo assessment, targeting improved IVF success rates while preserving embryo integrity.
Its diagnostic requires no embryo biopsy and no change to clinical workflow, relying instead on the culture medium already used in the laboratory, and it integrates multiple data types (molecular, imaging, genetic and clinical) rather than a single modality.
Technology
The core approach is non-invasive analysis of molecular signals (metabolomics) from the embryo's spent culture medium, combined with machine learning. The company reports a machine-learning model that predicts clinical pregnancy with 72% accuracy, and describes convergence of patient data, time-lapse images, genetics and metabolomics diagnosis. The method avoids embryo biopsy and is designed to integrate into existing lab processes. The company's public website runs on WordPress with the Divi page builder, Apache HTTP Server, PHP, MySQL and jQuery.
Go-to-market
Fertility clinics, reproductive medicine centers and IVF laboratories, and by extension patients undergoing IVF treatment.
Geography
The company works with fertility centers across the United States, Latin America and Europe. Company listings place it in Buenos Aires, Argentina.
History
The company was founded in 2020, approximately four years before a 2025 account by its CEO. Founder Delfina Vilieri connected with her scientific co-founders through the Grid Exponential accelerator. The company subsequently expanded its clinic relationships across the U.S., Latin America and Europe, raised funding, and participated in Techstars.
Risks & controversies
The founder describes biotech-specific challenges including long timelines, delayed results, the need to generate clinical evidence and navigate regulatory pathways, and balancing scientific and commercial development.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsEmbryoxite reports collaborating with fertility centers across the United States, Latin America and Europe to build a clinical dataset and advance clinical validation.
The company is listed as a Techstars '25 company, and its founder describes participating in international programs including Techstars.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- Embryoxite (Techstars '25) Overview, Address & Contactprospeo.io · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Embryoxite do?
- Biotech developing AI-based, non-invasive embryo selection for IVF using culture-medium metabolomics, imaging and clinical data.
- Who founded Embryoxite?
- Embryoxite was founded by Delfina Vilieri in 2020.
- Who are Embryoxite's investors?
- Embryoxite's investors include GRIDX, Techstars.
- Where is Embryoxite headquartered?
- Embryoxite is headquartered in Florida, US.